Opus Genetics officer proposes $110K share sale

The sale is described as not discretionary because it is required to cover any tax liability.

Available on EDGAR 11/03/2026 - 03:51 PM EST Accepted by SEC EDGAR 11/03/2026 - 03:50 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Opus Genetics (IRD) officer George N. Magrath reported a proposed sale of 28,258 common shares, with an aggregate market value of $110,183.59. The notice lists an approximate sale date of November 3, 2026, through Raymond James & Associates, Inc., on Nasdaq, and says the sale is not discretionary because it is required to cover tax liability. A separate entry lists 100,000 common shares acquired November 1, 2026, through an RSU grant vest.

Key Figures

Proposed sale: 28,258 common shares Aggregate market value: $110,183.59 Common shares acquired: 100,000 shares +3 more

6 metrics

Proposed sale 28,258 common shares Approximate sale date: November 3, 2026

Aggregate market value $110,183.59 Proposed sale

Common shares acquired 100,000 shares RSU grant vest on November 1, 2026

Shares outstanding 83,195,823 shares Reported in the securities information

Prior shares sold 9,591 common shares October 23, 2026

Prior sale aggregate market value $34,384.00 Sale on October 23, 2026

Key Terms

Rule 144, RSU GRANT VEST, Aggregate market value

3 terms

Rule 144 regulatory

"definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

RSU GRANT VEST financial

"Nature of acquisition: RSU GRANT VEST"

Aggregate market value financial

"Aggregate market value of securities to be sold"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IRD shares is George N. Magrath proposing to sell?

George N. Magrath, an Opus Genetics officer, reported a proposed sale of 28,258 common shares with an aggregate market value of $110,183.59; the approximate sale date is November 3, 2026. The sale is described as not discretionary because it is required to cover any tax liability.

What prior share sale does the IRD notice list for George N. Magrath?

The prior-sales table lists 9,591 common shares sold on October 23, 2026, with an aggregate market value of $34,384.00.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001999390
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Opus Genetics, Inc.
SEC File Number	001-34079
Address of Issuer	8 DAVIS DRIVE SUITE 220 DURHAM NORTH CAROLINA 27713
Phone	(984) 884-6030
Name of Person for Whose Account the Securities are To Be Sold	Magrath George
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	Raymond James & Associates, Inc. 880 Carillon Parkway St. Petersburg, FL 33716	28258	110183.59	83195823	11/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	11/01/2026	RSU GRANT VEST	ISSUER			100000	11/03/2026	CASH

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
GEORGE MAGRATH 401 PATJENS LANE MOUNT PLEASANT SC 29464	COMMON	10/23/2026	9591	34384.00

144: Remarks and Signature

Remarks	TRADE IS NOT DISCRETIONARY AS SALE IS REQUIRED TO COVER ANY TAX LIABILITY
Date of Notice	11/03/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Rashida Mitchell, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for George N Magrath
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)